Fortfahren mit
Anmelden zur Ansicht der Organisations- und Vertragspreise.
Größe auswählen
Ansicht ändern
| Packungsgröße | SKU | Verfügbarkeit | Preis |
|---|---|---|---|
| 5 mg | Warenkorb auf Verfügbarkeit prüfen | CHF 104.00 CHF 88.40 | |
| 25 mg | Warenkorb auf Verfügbarkeit prüfen | CHF 418.00 CHF 355.30 |
Über diesen Artikel
Empirische Formel (Hill-System):
C30H35NO3
CAS-Nummer:
Molekulargewicht:
457.60
NACRES:
NA.77
UNSPSC Code:
12352200
MDL number:
Assay:
≥95% (HPLC)
Form:
film or powder (or oil)
CHF 88.40
ListenpreisCHF 104.00Sparen Sie 15%Aktion nur im Web
Warenkorb auf Verfügbarkeit prüfen
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhaltenProduktname
Ormeloxifene, ≥95% (HPLC)
assay
≥95% (HPLC)
form
film or powder (or oil)
color
colorless to yellow-white
storage temp.
2-8°C
SMILES string
CC([C@@H](C1=CC=CC=C1)[C@@H]2C3=CC=C(OCCN4CCCC4)C=C3)(C)OC5=C2C=CC(OC)=C5
InChI
1S/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3/t28-,29+/m1/s1
InChI key
XZEUAXYWNKYKPL-WDYNHAJCSA-N
Biochem/physiol Actions
Ormeloxifene (Centchroman) is a non-steroidal selective estrogen receptor modulator (SERM) that exhibit anticancer activity. Ormeloxifene suppresses the ovariectomy-induced bone resorption in rats.
non-steroidal selective estrogen receptor modulator (SERM)
1 of 1
Dieser Artikel | |||
|---|---|---|---|
| assay ≥95% (HPLC) | assay ≥98% (HPLC) | assay ≥98% (HPLC) | assay ≥98% (HPLC) |
| form film or powder (or oil) | form powder | form powder | form powder |
| storage temp. 2-8°C | storage temp. 2-8°C | storage temp. 2-8°C | storage temp. 2-8°C |
| color colorless to yellow-white | color - | color - | color white to beige |
Lagerklasse
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Hier finden Sie alle aktuellen Versionen:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
William R Surin et al.
Journal of basic and clinical physiology and pharmacology, 1-8 (2014-01-29)
Abstract Background: Cancer is one of the leading causes of morbidity and mortality globally. Cancer-associated thrombosis is well established in clinical settings, and thrombin has been found to induce angiogenesis at cancer sites. This establishes a link between cardiovascular diseases
Geetika Kharkwal et al.
Journal of molecular endocrinology, 48(3), 261-270 (2012-04-12)
Ormeloxifene (Orm), a triphenylethylene compound, has been established as a selective estrogen receptor modulator (SERM) that suppresses the ovariectomy-induced bone resorption in rats. However, the precise mechanism underlying the bone-preserving action of Orm remains unclear. In this study, we evaluated
Bilal Bin Hafeez et al.
Molecular cancer therapeutics, 16(10), 2267-2280 (2017-06-16)
Ormeloxifene is a clinically approved selective estrogen receptor modulator, which has also shown excellent anticancer activity, thus it can be an ideal repurposing pharmacophore. Herein, we report therapeutic effects of ormeloxifene on prostate cancer and elucidate a novel molecular mechanism
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SML2237-5MG | 04061835494774 |
| SML2237-25MG | 04061835494767 |



